Suicide-Gene t cells aim to stop blood cancer relapse

NCT ID NCT04180059

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if needed. Six adults with certain blood cancers who have already received a transplant from a donor without that protein will receive increasing doses of these cells. The main goal is to find a safe dose that does not cause severe graft-versus-host disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell chronic lymphocytic leukemia classic Hodgkin lymphoma hematologic disorder hematopoietic and lymphoid system neoplasm myelodysplastic syndrome myeloproliferative neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chu de Nantes

    RECRUITING

    Nantes, France

    Contact Email: •••••@•••••